{"schema_version":"secwatch.filing_event.v1","accession":"0000950170-23-013276","form_type":"8-K","ticker":"FNCHQ","cik":"0001733257","company_name":"Finch Therapeutics Group, Inc.","filed_at":"2023-04-18T23:59:59+00:00","discovered_at":"2026-05-14T18:03:40.285642+00:00","generated_at":"2026-06-17T00:48:44.902492+00:00","sec_items":["1.01","7.01","9.01"],"event_type":"other_material","sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"confidence":"high","headline":"Finch Therapeutics announces ulcerative colitis trial for CP101, amends UMN license","bullets":["Investigator-sponsored trial at Brigham and Women's Hospital comparing two doses of CP101 in mild-to-moderate ulcerative colitis; topline data expected in 2025.","Amendment to University of Minnesota license allows Finch to satisfy performance milestones via sublicensing, aligning with new partnership-focused strategy.","Finch exclusively licenses 13 issued patents and 7 patent applications covering human fecal microbe formulations and microbiota diversity methods.","Clinical trial designed to generate data on safety, PK, PD, and clinical efficacy, building on microbiome evidence in ulcerative colitis."],"urls":{"canonical":"https://secwatch.observer/filing/0000950170-23-013276","json":"https://secwatch.observer/filing/0000950170-23-013276.json","markdown":"https://secwatch.observer/filing/0000950170-23-013276.md","text":"https://secwatch.observer/filing/0000950170-23-013276.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1733257/000095017023013276/0000950170-23-013276-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1733257/000095017023013276/fnch-20230412.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-17T00:48:44.902492+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"8a07aa5a3df9baaafdeaedf20243a7ac03cfa943","claim":"Finch Therapeutics Group, Inc. amended Amended and Restated Exclusive License Agreement with Regents of the University of Minnesota valued at amended terms related to performance milestones, including extension of deadlines and expansion of r (effective 2023-04-12).","evidence_excerpt":"On April 12, 2023, Finch Therapeutics Holdings LLC (“FTH”), a direct, wholly owned subsidiary of Finch Therapeutics Group, Inc. (the “Company”), and the Regents of the University of Minnesota (“UMN”), entered into an amendment (the “Amendment”) to the Amended and Restated Exclusive License Agreement, dated January 28, 2022, between FTH and UMN (the “UMN Agreement”).","evidence_source":"SEC 8-K Item 1.01/1.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1733257/000095017023013276/0000950170-23-013276-index.htm","confidence":0.9,"family_label":"Material Agreements","details":[{"label":"Action","value":"amendment"},{"label":"Agreement","value":"license"},{"label":"Counterparty","value":"Regents of the University of Minnesota"},{"label":"Value","value":"amended terms related to performance milestones, including extension of deadlines and expansion of r"},{"label":"Effective","value":"2023-04-12"}],"fact_type":"material_agreement"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}